Latest Breaking News On - ஷாங்காய் நகராட்சி ஆரோக்கியம் தரகு - Page 1 : comparemela.com
Comprehensive metabolomics profiling reveals common metabolic alterations underlying the four major non-communicable diseases in treated HIV infection
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
Why my Chinese parents hid my cancer diagnosis from me
asiaone.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from asiaone.com Daily Mail and Mail on Sunday newspapers.
By:Wu Qiong |
From:english.eastday.com | 2021-07-16 08:00
The fourteenth Five-Year Plan for Shanghai’s health development was outlined at a press conference held on Thursday, July 15.
Ms. Zong Ming, vice mayor of Shanghai mentioned the municipality’s specific goals. Three main goals for 2021-2025 are: a high-quality people-centered health service system; a health tech innovation center with global influence and a world example of a healthy city; and one of the world’s most complete public health systems.
Under the blueprint, Shanghai’s average life expectancy is to reach over 71 years old by 2025, and citizens’ health literacy rate is to surpass 36%.
Shanghai s health promotion efforts bear fruit
ecns.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ecns.cn Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
ResearchAndMarkets.com s offering.
The sales of hydroxychloroquine in the Chinese market have been rising steadily, from CNY 258 million in 2016 to CNY 343 million in 2020, with a CAGR of 7.34% from 2016 to 2020. In 2020, China s sales of hydroxychloroquine were CNY 343 million, a slight increase of 0.71% than 2019.
Hydroxychloroquine is commonly used to prevent and treat malaria. The pharmacokinetics of hydroxychloroquine is similar to that of chloroquine. It can be rapidly absorbed in the gastrointestinal tract and excreted in the kidneys. Hydroxychloroquine is also used in the treatment of rheumatoid arthritis, lupus erythematosus, and delayed skin lesions purpura.
The market demand for hydroxychloroquine in China is relatively large. There are two companies approved for manufacturing hydroxychloroquine, namely Shanghai Zhongxi Pharmaceutical Co., Ltd. and Sanofi-aventis Ireland Ltd. Shanghai Zhongxi Pharmaceutical Co., Ltd. has a larger